WHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
WHR is not a good buy right now for an impatient buyer. The stock is in a confirmed downtrend (bearish moving-average stack and weakening MACD), and the latest quarter plus FY2026 guidance were both below expectations, which keeps downside pressure elevated. Without an Intellectia buy signal and with price still below the key pivot (~82.33), the risk/reward is not attractive for an immediate entry.
Price/levels: Last close ~79.76 after a strong regular-session bounce (+3.94%), but still below the pivot resistance at ~82.33. Nearby support sits at ~75.58 (S1), then ~71.42 (S2). Resistance levels are ~89.07 (R1) and ~93.24 (R2). Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5, indicating the dominant trend remains down. Momentum: MACD histogram is negative (-0.969) and expanding bearishly, suggesting downside momentum is still building rather than reversing. RSI: RSI(6) ~39.9, leaning weak (not deeply oversold), implying there may still be room for further downside before a durable technical rebound. Pattern/near-term odds (provided): Similar-pattern stats imply modest upside potential over a week/month, but that conflicts with the currently bearish momentum/MA setup—so any bounce looks more like a trading bounce than a confirmed trend reversal.
Intellectia Proprietary Trading Signals
can support a rebound if news flow stabilizes.
fell short of expectations, reinforcing a cautious demand/margin outlook.
Latest quarter: 2025/Q4. Growth trends: Revenue fell to ~$4.098B (-0.92% YoY). Profitability deteriorated sharply: Net income ~$108M (down ~127.55% YoY), EPS 1.91 (down ~126.98% YoY), and gross margin 13.88% (down ~13.52% YoY). Overall, the quarter shows weakening demand/margins and a clear negative earnings trajectory into the new year.
No explicit analyst rating/price-target change data was provided. Based on the reported earnings miss and below-consensus FY2026 EPS outlook, the typical Wall Street setup here is: Pros—potential valuation/mean-reversion appeal after a selloff and a well-known brand with cyclical recovery optionality; Cons—near-term demand softness, margin compression, and lowered earnings expectations that often trigger price-target cuts and a more cautious stance.
